506414 Stock Overview
Manufactures and markets chemicals, bulk drugs, enzymes in India, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Fermenta Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹370.75 |
| 52 Week High | ₹354.60 |
| 52 Week Low | ₹145.00 |
| Beta | 0.25 |
| 11 Month Change | 26.13% |
| 3 Month Change | 23.09% |
| 1 Year Change | 137.66% |
| 33 Year Change | 30.18% |
| 5 Year Change | 80.93% |
| Change since IPO | 3,607.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 506414 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 16.8% | 0.5% | 0.5% |
| 1Y | 137.7% | 42.5% | 27.5% |
Return vs Industry: 506414 exceeded the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: 506414 exceeded the Indian Market which returned 27.5% over the past year.
Price Volatility
| 506414 volatility | |
|---|---|
| 506414 Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 506414 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 506414's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1951 | 558 | Prashant Nagre | fermentabiotech.com |
Fermenta Biotech Limited, together with its subsidiaries, manufactures and markets chemicals, bulk drugs, enzymes in India, Europe, the United States, and internationally. The company engages in the pharmaceutical formulations and environmental solutions; rents and sales properties; and sports and health awareness/education activities. It offers various variants of vitamin D3, including crystalline oil, resin oil, cold water dispersible, and feed grade powder used in applications, such as pharmaceuticals, dietary and nutritional supplements, feed, injectables, soft gel capsules, premixes, food and beverage fortification, veterinary, feed and rodenticides; pharmaceutical ingredients comprising of phenyramidol and silicon dry powder; nutritional premixes; and enzymes, used in pharmaceuticals, food and fragrances, oleo, biodiesel, leather, fine chemical, bio-plastics, and cosmetic industries.
Fermenta Biotech Limited Fundamentals Summary
| 506414 fundamental statistics | |
|---|---|
| Market cap | ₹9.60b |
| Earnings (TTM) | ₹84.68m |
| Revenue (TTM) | ₹3.69b |
128.9x
P/E Ratio3.0x
P/S RatioIs 506414 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 506414 income statement (TTM) | |
|---|---|
| Revenue | ₹3.69b |
| Cost of Revenue | ₹1.48b |
| Gross Profit | ₹2.22b |
| Other Expenses | ₹2.13b |
| Earnings | ₹84.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.88 |
| Gross Margin | 60.02% |
| Net Profit Margin | 2.29% |
| Debt/Equity Ratio | 41.5% |
How did 506414 perform over the long term?
See historical performance and comparison